Chalfont, PA (PRWEB) April 19, 2012
Today, Genomind announced the addition of John E. Johnson III as Senior Vice President, Sales. Mr. Johnson will be facilitating the national commercial launch of the Genecept Assay. Mr. Johnson brings over ten years of impressive healthcare sales and strategy experience to Genomind.
“John will be critical to the commercial adoption of the Genecept Assay,” said Scott A. Storrer, President and CEO of Genomind. “His experience and record of success are exceptional and we look forward to him joining our strong team of executives.”
Mr. Johnson will be responsible for leading all sales and commercialization efforts at Genomind. Prior to joining Genomind, Mr. Johnson served as Sales Director for Dermpath Diagnostics, a $270 million cancer diagnostics division of Quest Diagnostics and formerly of AmeriPath, Inc . Mr. Johnson spent over 10 years with Dermpath Diagnostics directing sales and marketing strategies, developing high performance sales teams, and providing strategic vision. He led a team of healthcare and diagnostics industry veterans and physicians to build Dermpath Diagnostics into the market leader in dermatopathology .
“I am excited to be joining the Genomind team,” said Johnson. “The Genecept Assay is a remarkable tool that has the potential to truly advance the field of neuropsychiatry. I am thrilled to have the opportunity to introduce it to clinicians nationwide.”
About the Genecept Assay
The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/products/assay.
Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.